Home › Atopic Dermatitis (Eczema) › Texas
Pag-aaral pangklinika para sa Atopic Dermatitis (Eczema) sa Texas
18 pag-aaral para sa Atopic Dermatitis (Eczema) ang naghahanap ng mga kalahok sa mga site sa Texas.
Mga Lungsod sa Texas
Opisyal na teksto ng pag-aaral (English)
Ph 1a/1b Single Ascending Dose and Multiple Ascending Dose Study of ARQ-234
- Clinical Site 102, College Station
- Clinical Site 104, San Antonio
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07453602This Study is a Non-interventional Disease Registry of Adolescent and Adult Patients With Atopic Dermatitis Who Initiate or Switch Any Systemic Treatment
- Reveal Research Institute - Dallas- Site Number : 8400012, Dallas
- Austin Institute for Clinical Research, Inc- Site Number : 8400030, Pflugerville
- Complete Dermatology - Sugar Land- Site Number : 8400001, Sugar Land
Nagre-recruitObservasyonal na pag-aaral
Edad 12 pataas · Lahat ng kasarian · Na-update Set 29, 2026 · NCT07290803Platform Study to Evaluate the Efficacy and Safety of Investigational Compound(s) in Patients With Moderate to Severe Atopic Dermatitis
- Novartis Investigative Site, Arlington
- Novartis Investigative Site, Cypress
- Novartis Investigative Site, Dallas
- at 2 pa
Nagre-recruitPhase 2
Edad 18 hanggang 100 · Lahat ng kasarian · Na-update Set 28, 2026 · NCT06947993Study of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Arlington
- Enveda Investigative Site, Houston
- Enveda Investigative Site, San Antonio
Nagre-recruitPhase 2
Edad 18 hanggang 75 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07298395First-in-Human Trial to Assess REGN20423 in Healthy Adult Participants and Adult Participants With Atopic Dermatitis
- Texas Dermatology and Laser Specialists, San Antonio
Nagre-recruitPhase 1Malugod na tinatanggap ang malusog na boluntaryo
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT07527923A Long-term Study of the Medicine Called Abrocitinib in Children Aged 2 Years and Older With Moderate to Severe Eczema
- Texas Dermatology and Laser Specialists, San Antonio
Nagre-recruitPhase 3
Edad 2 hanggang 11 · Lahat ng kasarian · Na-update Set 25, 2026 · NCT06807281A Long-term Safety and Efficacy Study Evaluating APG777 in Atopic Dermatitis
- Investigational Site, Dallas
- Investigational Site, Frisco
- Investigational Site, San Antonio
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Set 23, 2026 · NCT07003425Evaluation of a Non-Invasive Device for Early Detection of Atopic Dermatitis Flares
- Harrison Dermatology, Missouri City
Nagre-recruitObservasyonal na pag-aaral
Edad 12 hanggang 89 · Lahat ng kasarian · Na-update Set 15, 2026 · NCT07645820A Double-Blind, Randomized, Vehicle-Controlled Phase 2 Study to Assess the Efficacy and Safety of GX-03 in Adult Subjects With Moderate to Severe Atopic Dermatitis (Eczema)
- ALS Global, Irving
Nagre-recruitPhase 2/3
Edad 18 hanggang 80 · Lahat ng kasarian · Na-update Set 4, 2026 · NCT07355075A Phase 2b Study of the Effects of Camoteskimab in Adults With Moderate-to-Severe Atopic Dermatitis
- Progressive Clinical Research, PA, San Antonio
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Ago 28, 2026 · NCT07599813A Study to Evaluate the Efficacy and Safety of IMG-007 in Adult Participants With Moderate-to-Severe Atopic Dermatitis
- Inmagene Site 8, Southlake
Nagre-recruitPhase 2
Edad 18 hanggang 74 · Lahat ng kasarian · Na-update Ago 12, 2026 · NCT07037901A Phase 2b Dose-Ranging Study to Evaluate the Efficacy and Safety of ENV-294 in Adults With Moderate-to-Severe Atopic Dermatitis
- Enveda Investigative Site, Dallas
- Enveda Investigative Site, San Antonio
- Enveda Investigative Site, Sugar Land
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT07643766A Study to Assess Adverse Events and Change in Disease Activity Comparing Oral Upadacitinib to Subcutaneous Dupilumab in Children From 2 to Less Than 12 Years of Age With Moderate to Severe Atopic Dermatitis
- Arlington Research Center, Inc /ID# 266330, Arlington
- 3A Research - East location /ID# 267622, El Paso
- Prime Clinical Research - Mansfield - East Broad Street /ID# 268042, Mansfield
- at 2 pa
Nagre-recruitPhase 3
Edad 2 hanggang 11 · Lahat ng kasarian · Na-update Ago 6, 2026 · NCT06461897A Study of Upadacitinib in Adult Participants With Moderate-to-Severe Atopic Dermatitis and Inadequate Response to Dupilumab
- Arlington Research Center, Inc /ID# 263665, Arlington
- Studies in Dermatology LLC /ID# 263335, Cypress
- Dermatology Treatment and Research Center /ID# 265812, Dallas
- at 6 pa
Nagre-recruitPhase 3
Edad 18 hanggang 63 · Lahat ng kasarian · Na-update Hul 6, 2026 · NCT06389136Evaluate Efficacy and Safety of Repeat Subcutaneous Doses of FB825 in Adults With Moderate-to-Severe Atopic Dermatitis
- UT Health Science Houston, Bellaire
- Center for Clinical Studies, Webster
Nagre-recruitPhase 2
Edad 18 hanggang 65 · Lahat ng kasarian · Na-update Hun 15, 2026 · NCT06397911A Study To Learn About Two Study Medicines (PF-07275315 And PF-07264660) In People Who Have Moderate To Severe Atopic Dermatitis
- Dermatology Treatment and Research Center, Dallas
- North Texas Center for Clinical Research, Frisco
- DCT-Stone Oak, LLC dba Discovery Clinical Trials, San Antonio
- at 1 pa
Nagre-recruitPhase 2
Edad 18 pataas · Lahat ng kasarian · Na-update May 4, 2026 · NCT05995964Real-world Experience Using Nemolizumab in the Treatment of Moderate-to-Severe Atopic Dermatitis in Adolescents & Adults
- Galderma Investigational Site 7082, Cedar Park
- Galderma Investigational Site 8238, Dallas
- Galderma Investigational Site 7062, Edinburg
- at 3 pa
Nagre-recruitObservasyonal na pag-aaral
Edad 12 pataas · Lahat ng kasarian · Na-update Mar 13, 2026 · NCT06988605Safety and Pharmacokinetics of LPX-TI641 in Atopic Dermatitis and Psoriasis
- Clinical Investigations of Texas, Dallas
Nagre-recruitPhase 1
Edad 18 pataas · Lahat ng kasarian · Na-update Dis 19, 2025 · NCT06982352Mula sa ClinicalTrials.gov, na-kuha noong Okt 5, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.